Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Interactive Tools
Sponsored
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
CDK4/6 Inhibitors for Hormone-Driven Breast Cancer
EP. 11: Treatment Selection for HR+ mBC
October 2nd 2017
EP. 12: Future Directions: CDK4/6 Inhibitors in Breast Cancer
October 2nd 2017
EP. 13: ER+/HER2+ Metastatic Breast Cancer
October 2nd 2017
EP. 14: CDK4/6 Inhibitor Combinations for HR+ mBC
October 2nd 2017
EP. 15: Understanding Abemaciclib: A New CDK4/6 Inhibitor
October 2nd 2017
EP. 16: Heterogeneity of Metastatic HR+ Breast Cancer
October 2nd 2017
EP. 17: Factors in Deciding Treatment for HR+ Breast Cancer
October 2nd 2017
EP. 18: HR+ Breast Cancer: Resistance to Primary Therapy
October 2nd 2017
EP. 19: HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3
October 2nd 2017
EP. 20: Abemaciclib's Value in Treating HR+ Breast Cancer
October 2nd 2017
NEXT PAGE
<
1
2
3
>
PREVIOUS PAGE